Methods of generating protein therapeutics in spirulina
Non-homologous end-joining and transposase-mediated gene swapping in spirulina transformation overcome the limitations of existing methods, enabling efficient production of therapeutic proteins for mucosal vaccination and disease treatment.
Patent Information
- Application Number
- PCT/US2026/026775
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Existing methods for transforming spirulina are laborious, prone to contamination, and rely on homologous recombination, which requires large plasmids and limits the flexibility of gene regulation and expression.
The use of non-homologous end-joining (NHEJ) and transposase-mediated gene swapping with expression cassettes lacking homology to the spirulina genome, allowing for efficient, stable integration of exogenous DNA and rapid experimentation with different regulatory sequences.
This approach simplifies and accelerates the production of spirulina strains capable of producing therapeutic proteins, enabling mucosal vaccination and disease treatment, such as for rotavirus and Clostridium difficile, by using axenic cultures and site-specific recombination.
Smart Images

Figure IMGF000001_0001 
Figure IMGF000002_0001 
Figure IMGF000003_0001
Abstract
Description
[0001]
[0002] METHODS OF GENERATING PROTEIN THERAPEUTICS IN SPIRULINA
[0003] CROSS-REFERENCE TO RELATED APPLICATIONS
[0004] This application claims prioirty of US Provisional Application number 63 / 800,408, filed May 5, 2025, the entire contents being incorporated herein by reference as though set forth in full.
[0005] REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[0006] The contents of the electronic sequence listing (MLH-144.PCT_Seq-Listing.xml; Size: 213,026 bytes; and Date of Creation: May 5, 2026) is hereby incorporated by reference in its entirety.
[0007] BACKGROUND OF THE INVENTION
[0008] Arthrospira platensis (commonly known as spirulina) is a photosynthetic cyanobacterium. It is a highly nutritious food that has been consumed for decades in the US, and even longer by indigenous cultures. Its widespread use as a safe food source and proven scalability have driven frequent attempts to convert it into a biomanufacturing platform. But these have been frustrated by spiruhna's genetic intractability.
[0009] The first successful spirulina transformation protocol that incorporated a mutation in the spirulina genome is disclosed in US Patent No. 10,131,870, the contents of which are incorporated herein by reference. Prior to this disclosure, it was notoriously difficult to stably introduce foreign DNA into spirulina. For example. Zhang (2001) teaches spirulina transformation using axenic spirulina cells, yet shows no evidence of stably incorporating a mutation in the spirulina genome. Toyomizu et al. (2001) attempted transformation using electroporation and Kawata et al. (2004) attempted transformation using a natural Tn5 transposon, transposase, and cation liposome complex by electroporation. Neither of these approaches resulted in a stable spirulina transformant. Other approaches to create stable mutations in the spirulina genome using chemicals have also failed. For instance, Fang (2013) used ARTP, a method that uses active chemical species at a high concentration to penetrate the cell membrane and damage the cell's DNA, causing random mutations and Yuanyuan (2013) teaches using ethylmethane sulfonate (EMS) which also causes random mutations. Neither of these approaches led to stable spirulina transformants.
[0010]
[0011] Prior art methods for A. platensis transformation rely on homologous recombination to introduce exogenous DNA into the A. platensis genome. These methods require very large plasmids for transformation, because they use -2000-4000 base pairs of homologous DNA to flank the transgene. They provide levels of expression that are determined by the promoters associated with the genomic insertion sites. Replacing an integrated DNA sequence (for instance, to iteratively test different genetic elements) is not faster or easier than obtaining the original transformant.
[0012] There is a need for a reliable system for efficiently transferring exogenous sequences into spirulina.
[0013] SUMMARY OF THE INVENTION
[0014] In a first aspect, a recombinant spirulina comprising an expression cassette is provided. The expression cassette includes a nucleic acid comprising an exogenous promoter sequence operably linked to a sequence encoding a polypeptide, wherein the expression cassette was incorporated into the genome using processes independent of homologous recombination. In certain embodiments, the expression cassette does not contain an endogenous spirulina gene and / or the homologous domains within the expression cassette have not undergone homologous recombination during their incorporation into the spirulina genome. In certain embodiments, the expression cassette contains one or more recognition sequences capable of mediating site-specific recombination. In certain embodiments, the exogenous promoter sequence is a high efficiency heterologous promoter sequence. In certain embodiments, the heterologous promoter sequence comprises a J23119 promoter sequence. In certain embodiments, the polypeptide is capable of inducing a mucosal immune response.
[0015] In certain embodiments, the expression cassette encodes a polypeptide sequence of interest. In certain embodiments, the polypeptide sequence of interest provides resistance to the toxic effects of blasticidin. In certain embodiments, the polypeptide sequence of interest provides resistance to the toxic effects of hygromycin. In certain embodiments, the polypeptide sequence of interest is an antibody or a vaccine (e.g. rotavirus or poliovirus).
[0016] In certain embodiments, the polypeptide is a Clostridium toxin or a fusion protein comprising a Clostridium toxin. In certain embodiments, the clostridial toxin is derived from C. botulinum, C. perfringens, or C. difficile. In certain embodiments, the clostridial
[0017]
[0018] toxin is fused to wherein the NetB toxin, influenza hemagglutinin (HA), or a fragment thereof.
[0019] In certain embodiments, the polypeptide is a cholera toxin or a fusion protein comprising a cholera toxin. In certain embodiments, the cholera toxin is the cholera toxin B subunit or the cholera toxin B subunit fused to a poliovirus antigen (BC loop polypeptide). In certain embodiments, the cholera toxin is the cholera toxin B subunit expressed with a c-terminal KDEL endoplasmic reticulum retention sequence comprising the amino acids Lys-Asp-Glu-Leu.
[0020] In certain embodiments, the polypeptide is an E. coli heat labile enterotoxin. In certain embodiments, the E. coli heat labile enterotoxin is the enterotoxin B subunit or the double mutant heat-labile enterotoxin B, specifically LT(R192G / L211A).
[0021] In another aspect of the invention, methods of generating the strain of spirulina of described herein are provided. In certain embodiments, the methods comprise contacting a native spirulina with the expression cassette. In certain embodiments, the native spirulina is in an axenic population. In certain embodiments, the methods further comprise treating with AHL (or other quorum sensing molecule). In certain embodiments, the expression cassette comprises an antibiotic resistance gene and the method further comprises contacting the spirulina with the antibiotic (Blasticidin, Hygromycin B). In certain embodiments, the methods further comprise performing electroporation or contacting the spirulina and / or expression cassette with cationic lipids that promote transformation of the spirulina.
[0022] In another aspect of the invention, methods generating a recombinant spirulina having a genome comprising an expression cassette are provided. In certain embodiments, the methods comprise a) contacting spirulina with a donor nucleic acid comprising a DNA sequence flanked by recombinase recognition sites, and b) contacting spirulina with nucleic acids encoding one or more recombinases, thereby effecting a swap of ectopic DNA sequences within the genome with donor DNA sequences.
[0023] In certain embodiments of the recombinant spirulina or methods described herein, the expression cassette has attP sites. In certain embodiments, the attP sites are specific for the transposases BxBl and PhiC21. In certain embodiments, the methods further comprise co-transfection with plasmids expressing transposases.
[0024] In another aspect of the invention, methods of mucosal administration of a protein of interest are provided. In certain embodiments, the methods comprise administering a
[0025]
[0026] recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding the protein of interest. In another aspect of the invention, methods of mucosal vaccination of a subject with a protein of interest are provided. In certain embodiments, the methods comprising administering a recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding the protein of interest. In certain embodiments, the methods comprise administering a recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding the protein of interest, thereby inducing a mucosal specific (IgA) immune response. In certain embodiments, the protein of interest is capable of specific interaction with mucosal microfold cells. In certain embodiments of the methods described herein, the protein of interest comprises a Clostridium toxin or a fusion protein comprising a Clostridium toxin.
[0027] In certain embodiments of the recombinant spirulina or methods described herein, the expression cassette lacks homology or lacks flanking sequences with homology to spirulina genome. In certain embodiments, the expression cassette does not contain an endogenous spirulina gene or a sequence sharing greater than 95% identity with a spirulina gene. In certain embodiments, the recombinant spirulina has a full-complement of genes expressed by a parental strain and / or the expression cassette does not disrupt expression of an endogenous spirulina gene locus.
[0028] In another aspect of the invention, recombinant spirulina produced according to the methods described herein are provided.
[0029] In another aspect of the invention, methods inducing a mucosal immune response in a subject are provided. In certain embodiments, the methods comprise administering a recombinant spirulina described herein to the subject. In certain embodiments, the administration is via an oral route.
[0030] In another aspect of the invention, recombinant spirulina comprising an expression cassette are provided. In certain embodiments, the expression cassette comprises a nucleic acid comprising an exogenous promoter operably linked to a sequence encoding a cholera toxin or a fusion protein comprising a cholera toxin. In certain embodiments, the expression cassette comprising a nucleic acid comprising an exogenous promoter and a
[0031]
[0032] sequence encoding a heat-labile toxin or a fusion protein comprising a heat-labile toxin. In certain embodiments, the fusion protein comprises a poliovirus vpl or fragment thereof.
[0033] Still other aspects and advantages of these compositions and methods for making the compositions and using the compositions are described further in the following detailed description of the preferred embodiments thereof.
[0034] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a map of plasmid YFP Blast.
[0035] FIG. 2 is a map of YFP Hygro.
[0036] FIG. 3 is a map of ARP1 ALFA E3.
[0037] FIG. 4 is a map of ARPl_ALFA_E3_mhYFP.
[0038] FIG. 5 is a map of ARPl ALFA dLANYFP.
[0039] FIG. 6 is a map of ARPl Fc.
[0040] FIG. 7 is a map of mAb 41 ALFA E3.
[0041] FIG. 8 is a map of mAb 41_ALFA_E3_mhYFP.
[0042] FIG. 9 is a map of mAb 41 ALFA dLANYFP.
[0043] FIG. 10 is a map of mAb 41_Fc.
[0044] FIG. 11 is a map of Perf_ALFA:T2A Blast.
[0045] FIG. 12 is a map of HWL-Del_blast.
[0046] FIG. 13 is a map ofHWLblast.
[0047] FIG. 14 is a map of Perf mini H3.
[0048] FIG. 15 is a map ofBoNT D.
[0049] FIG. 16 is a map of HL ETB ALFA T2A Blast.
[0050] FIG. 17 is a map of CTxB ALF A T2A Blast.
[0051] FIG. 18 is a map of BC loop_HL_ETB_T2A Blast.
[0052] FIG. 19 is a map of BC loop_CTxB_T2A Blast.
[0053] FIG. 20 is a map of MEFl_30_l_v2SM_WT.
[0054] FIG. 21 is a map of MEFl_30_l_v2SM_FOX.
[0055] FIG. 22 is a map of MEFl_30_l_v2SM_BLUE.
[0056] FIG. 23 is a map of CTXB SEKDEL (.
[0057] FIG. 24 is a map of CTXB CB SEKDEL.
[0058] FIG. 25 is Transformed A. platensis expressing ectopic mhYFP genes. Three strains are shown imaged by fluorescence microscopy, CTXB-BC-SEKDEL. CTXB-SEKDEL, and
[0059]
[0060] MEF1_3O_1_V2SM_BLUE, 5-6 weeks after undergoing DNA transformation.
[0061] Incorporation of the transforming DNA is indicated by ectopic expression of YFP in each of the three cultures. A. platensis cells are also shown by fluorescence imaging of the C-phy cocyanin pigment. Scale bar = 100 microns.
[0062] FIG. 26A-26F: Sequences for YFP Blast.
[0063] FIG. 27A-27G: Sequences for YFP Hygro.
[0064] FIG. 28A-28B: Sequences for S3 ARP1 ALFA E3.
[0065] FIG. 29A-29C: Sequences for S4 ARP1 ALFA E3.
[0066] FIG. 30A-30B: Sequences for ARPl ALFA dLA.
[0067] FIG. 31A-31B: Sequences for ARPl FcTag vf
[0068] FIG. 32A-32C: Sequences for mAB_41_ALFA_E.
[0069] FIG. 33A-33C: Sequences for mAb_41_ALFA_E.
[0070] FIG. 34A-34C: Sequences for mAB_41_ALFA_d.
[0071] FIG. 35A-35C: Sequences for mAB_41_FcTag.
[0072] FIG. 36A-36B: Sequences for Perf_ALFA:T2.
[0073] FIG. 37A-37C: Sequences for HWL-del bias.
[0074] FIG. 38A-38C: Sequences for HWL_blast_vf.
[0075] FIG. 39A-39C: Sequences for Perf_ALFA_M2.
[0076] FIG. 40A-40C: Sequences for BoNTD ALFA.
[0077] FIG. 41A-41B: Sequences for HL ETB ALFA.
[0078] FIG. 42A-42C: Sequences for CTxB_ALFA_T2.
[0079] FIG. 43A-43B: Sequences for BC loop HL E.
[0080] FIG. 44A-44B: Sequences for BC loop CTxB.
[0081] FIG. 45A-45K: Sequences for MEFl_30_l_v2SM_WT.
[0082] FIG. 46A-46G: Sequences for MEFl_30_l_v2SM_FOX.
[0083] FIG. 47A-47G: Sequences for MEFl_30_l_v2SM_BLUE.
[0084] FIG. 48A-48D: Sequences for CTXB SEKDEL.
[0085] FIG. 49A-49H: Sequences for CTXB CB SEKDEL.
[0086] FIG. 50A-50J: Additional sequences for MEFl_30_l_v2SM_WT, MEFl_30_l_v2SM_WT FOX, MEFl_30_l_v2SM_BLUE, CTXB SEKDEL and CTXB CB SEKDEL.
[0087] DETAILED DESCRIPTION
[0088]
[0089] Provided herein are novel materials and methods for genetic transformation of Arthrospira platensis (Spirulina), as well as strains of A. platensis that contain genetic elements to allow transposase mediated replacement of transgenes.
[0090] The potential to use spirulina to treat and prevent mucosal infections through mucosal vaccination has been completely unexplored, despite long-standing co-existence of relevant information in the literature, which attests to its non-obviousness. We first reported that botulinum toxin C-terminal domains (CTDs) can be used to induce mucosal immunity (after nasal application) in 2007
[0018] , Knowledge of the ability of cholera toxin B (CTB) serve as a mucosal immunogen fused to heterologous polypetides has existed since 1990, and its immunological similarity to heat labile enterotoxin B subunit (HLEB) since 2001 [19, 20], The ability for the C. perfringens CTD to play the same role was published in 2012
[0021] ,
[0091] In addition, spirulina genetic transformation has been a subject of study for at least 20 years
[0022] , and the foremost company in spirulina transformation, Lumen Bioscience, has been in business since 2017. Nonetheless, no mucosal vaccine that uses a bacterial protein adjuvant known to stimulate mucosal immunity, such as those described here, has been reported, in particular clostridial toxins, cholera toxin B (CTB, CTxB), and the heat labile enterotoxin B subunit (HLEB). Lastly, the application of spirulina for treatment of rotavirus has also been ignored, despite reports of the potential efficacy of this approach dating back to 1994 [8],
[0092] The prior art methods for transforming spirulina are laborious and slow [1], Spirulina cultures are prone to contamination and in fact, the transformation methods used by others require that spirulina be cultured in the presence of contaminating bacteria for transformation. Spirulina need to be separated from contaminant organisms following transformation, by laborious procedures that may include cell cloning, cell sorting, and antibiotic treatment. The methods described herein work with pure, uncontaminated spirulina cultures, which simplifies and accelerates the transformation procedure.
[0093] The present methods use non-homologous end-j oining (NHEJ) to introduce DNA into the spirulina genome, in contrast to prior methods that rely on homologous recombination that occurs between sequences in the transforming DNA and the spirulina genomic DNA. The DNA vectors used are notable for polylinker sequences that allow the plasmid DNAs to be digested with restriction enzymes before transformation that leave different types of DNA ends (5' overhang, 3' overhang, and blunt), which may have
[0094]
[0095] differential effects on the efficiency and sites of NHEJ. An additional drawback of previous methods is that homologous recombination requires 2000-4000 bases of homologous DNA be present in the transforming sequences. This inconveniently increases the size of the plasmids to be used, whereas in general, shorter plasmids and genes are ideal for managing the technical aspects of gene construction, delivery, and expression.
[0096] Prior art methods are also limited in scope and applicability by their dependence on homologous recombination for genome targeting with exogenous DNA. Transgenes are regulated by endogenous regulatory sequences that cannot be easily changed to experiment with different regulatory sequences or introduce gene induction or repression capabilities. New homologous sites will need to be identified and used to provide variability in transgene expression. In the present invention, gene control sequences are within the transforming DNA, for example in these inventions, allowing use of the J23119 promoter (Part:BBa_J23119). Antibiotic regulatable promoters can also be introduced using the present methods, for example
[0023] ,
[0097] In the prior art, each strain of spirulina needs to be made anew via homologous recombination. Variant protein encoding sequences cannot be replaced in a spirulina strain using any short-cut methods, which would be helpful because they would accelerate the pace of experimentation, for example, to determine which DNA constructs are able to give the most efficient production of the desired protein. In the present invention, target recombination sites for the transposases Bxbl and PhiC31 (a Landing Pad) flank the transgenes and their regulatory sequences. DNA electroporation of transformed spirulina strains with plasmids that contain appropriate transposase donor sequences, in addition to plasmids expressing the transposase proteins, can allow a swap between incorporated sequences and novel (donor) sequences
[0024] , Compared to prior art methods, this speeds experimentation to develop critically important knowledge about the regulation and expression of exogenous proteins by spirulina and the development of new spirulina strains.
[0098] The methods and cells are improvements compared to the prior art because they simplify and accelerate the production of A. platensis strains that produce molecules useful for the prevention and treatment of diseases.
[0099] Examples of molecules to be produced (and thereby delivered through oral administration of A. platensis) include monoclonal antibodies specific for poliovirus (for treatment of chronic poliovirus infection and reduction in viral shedding), Clostridium
[0100]
[0101] difficile (for treatment of antibiotic-associated colitis), and biofilm amyloids (for treatment of inflammatory bowel diseases characterized by intestinal biofilms).
[0102] The recitation “polynucleotide” or "nucleic acid” as used herein designates mRNA, RNA, cRNA, rRNA, cDNA, or DNA. The term typically refers to polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The term includes single and double stranded forms of DNA and RNA.
[0103] As used herein, the term "DNA” includes a DNA molecule that has been isolated free of total genomic DNA of a particular species. Therefore, a DNA segment encoding a polypeptide refers to a DNA segment that contains one or more coding sequences yet is substantially isolated away from, or purified free from, total genomic DNA of the species from which the DNA segment is obtained. Included within the terms “DNA segment” and “polynucleotide” are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phagemids, phage, viruses, and the like.
[0104] With regard to polynucleotides, the term “exogenous” refers to a polynucleotide sequence that does not naturally occur in a wild-type cell or organism, but is typically introduced into the cell by molecular biological techniques. Examples of exogenous polynucleotides include vectors, plasmids, and / or man-made nucleic acid constructs encoding a desired protein. With regard to polynucleotides, the term "endogenous” or “native” refers to naturally occurring polynucleotide sequences that may be found in a given wild-type cell or organism. A vector, plasmid, or other man-made construct that includes an endogenous polynucleotide sequence combined with polynucleotide sequences of the unmodified vector etc. is, as a whole, an exogenous polynucleotide and may also be referred to as an exogenous polynucleotide including an endogenous polynucleotide sequence. Also, a particular polynucleotide sequence that is isolated from a first organism and transferred to second organism by molecular biological techniques is ty pically considered an “exogenous” polynucleotide with respect to the second organism.
[0105] Polynucleotides may comprise a native sequence or may comprise a variant or fragment, or a biological functional equivalent of such a sequence. Polynucleotide variants may contain one or more substitutions, additions, deletions and / or insertions, as further described herein, preferably such that the enzymatic activity of the encoded polypeptide is not substantially diminished relative to the unmodified or reference polypeptide. The
[0106]
[0107] effect on the enzymatic activity of the encoded polypeptide may generally be assessed as described herein and known in the art.
[0108] ‘'Polypeptide.’7“polypeptide fragment,” “peptide,” and “protein” are used interchangeably herein to refer to a polymer of amino acid residues and to variants and synthetic analogues of the same. Thus, these terms apply to amino acid polymers in which one or more amino acid residues are synthetic non-naturally occurring amino acids, such as a chemical analogue of a corresponding naturally occurring amino acid, as well as to naturally-occurring amino acid polymers. In certain aspects, polypeptides may include enzymatic polypeptides, or “enzy mes,” which typically catalyze (i.e., increase the rate of) various chemical reactions. Exemplary nucleotide sequences that encode the proteins and enzymes of the application encompass full-length reference polynucleotides, as well as portions of the full-length or substantially full-length nucleotide sequences of these genes or their transcripts or DNA copies of these transcripts. Portions of a nucleotide sequence may encode polypeptide portions or segments that retain the biological activity of the reference polypeptide.
[0109] “Transformation” refers to the stable, heritable alteration in a cell resulting from the uptake and incorporation of exogenous nucleotides into the host-cell genome; also, the transfer of an exogenous gene from one organism into the genome of another organism. Exogenous nucleotides may include genes foreign to the target organism or addition of a nucleotide sequence present in the wild-type organism.
[0110] “Stable” when describing the results of a genetic modification caused by transformation refers to a genetic modification that is maintained in at least a portion of a population of cells for ten or more generations or for a length of time equal or greater to ten times the average generation time for the modified organism.
[0111] “Competent” refers to the ability of a cell to take up extracellular nucleotides from the surrounding environment. A cell may7be “naturally competent” or “artificially7competent.” Naturally competent cells are able to take up nucleotides from their surrounding environment under natural conditions. Artificially competent cells are made passively permeable to extracellular nucleotides by exposing the cell to conditions that do not normally occur naturally including incubation in a solution of divalent cations, heat shock, electroporation, and ultrasound.
[0112] The terms “wild-type” and “naturally occurring” are used interchangeably to refer to an organism, gene, or gene product that has the characteristics of that organism, gene or
[0113]
[0114] gene product (e.g., a polypeptide) when isolated from a naturally occurring source. A wild-type organism, gene, or gene product is that which is most frequently observed in a population and is thus arbitrarily designed the "normal" or "wild-type” form.
[0115] By “vector” is meant a polynucleotide molecule, preferably a DNA molecule derived, for example, from a plasmid, bacteriophage, yeast, or virus, into which a polynucleotide can be inserted or cloned. A vector may contain one or more synthetic nucleotides or nucleic acid analogues. A vector may contain one or more unique restriction sites. A vector system can comprise a single vector or plasmid, two or more vectors or plasmids, some of which increase the efficiency of targeted mutagenesis, or a transposition. The choice of the vector will typically depend on the compatibility' of the vector with the host cell into which the vector is to be introduced. The vector can include a reporter gene, such as a green fluorescent protein (GFP), which can be either fused in frame to one or more of the encoded polypeptides, or expressed separately. The vector can also include a positive selection marker such as an antibiotic resistance gene that can be used for selection of suitable transformants. The vector can also include a negative selection marker such as the type II thioesterase (tesA) gene or the Bacillus subtilis structural gene (sacB). Use of a reporter or marker allow s for identification of those cells that have been successfully transformed with the vector.
[0116] “Patient” or “subject” or “individual” as used herein means a mammalian animal, including a human, a veterinary or farm animal, a domestic animal or pet, and animals normally used for clinical research. In one embodiment, the subject of these methods and compositions is a human. In another embodiment, the subject is a farm animal. In another embodiment, the subject is a chicken. In another embodiment, the subject is a pig. In another embodiment the subject is ahorse, cow, sheep, goat, duck, goose, rabbit, or other farm animal.
[0117] The term “isolated” designates a biological material (nucleic acid or protein) that has been removed from its original environment (the environment in which it is naturally present). For example, a polynucleotide present in its natural state in a plant or an animal is not isolated, however the same polynucleotide separated from the adjacent nucleic acids in which it is naturally present, is considered “isolated”. The term “purified” does not require the material to be present in a form exhibiting absolute purity, exclusive of the presence of other compounds.
[0118]
[0119] The terms “percent (%) identity”, “sequence identity”, “percent sequence identity”, or “percent identical” in the context of amino acid sequences or nucleotide sequences refers to the residues in the two sequences which are the same when aligned for correspondence. Percent identity may be readily determined for amino acid sequences or nucleotide sequences over the full-length of a protein, polypeptide, or encoding region thereof, e.g., about 15 amino acids, about 150 amino acids, or a peptide fragment thereof or the corresponding nucleic acid sequence coding sequences. A suitable amino acid fragment may be at least about 4 amino acids in length and may be up to about 200 or up to about 700 amino acids or nucleotide fragments of from about 12 nucleotides to about 600 to 2100 nucleotides. Generally, when referring to “identity”, “homology ”, or “similarity’” between two different sequences, “identity’”, “homology’” or “similarity” is determined in reference to “aligned” sequences. “Aligned” sequences or “alignments” refer to multiple nucleic acid sequences or protein (amino acids) sequences, often containing corrections for missing or additional bases or amino acids as compared to a reference sequence. Alignments are performed using any of a variety of publicly or commercially available Multiple Sequence Alignment Programs. Sequence alignment programs are available for amino acid sequences, e.g., the “Clustal Omega”, “Clustal X”, “MAP”, “PIMA”, “MSA”, “BLOCKMAKER”, “MEME”, and “Match-Box” programs. Generally, any of these programs are used at default settings, although one of skill in the art can alter these settings as needed. Alternatively, one of skill in the art can utilize another algorithm or computer program yvhich provides at least the level of identity or alignment as that provided by the referenced algorithms and programs. See, e.g., (THOMPSON et al. 1999).
[0120] In the descriptions of the compositions and methods discussed herein, the various components can be defined by use of technical and scientific terms having the same meaning as commonly understood by one of ordinary skill in the art to yvhich this invention belongs and by reference to published texts. Such texts provide one skilled in the art with a general guide to many of the terms used in the present application. The definitions contained in this specification are provided for clarity in describing the components and compositions herein and are not intended to limit the claimed invention.
[0121] Methods for transformation and culture of spirulina
[0122]
[0123] Disclosed are DNA vectors and selectable marker genes that allow rapid introduction and stable expression of transforming DNA, using non-homologous end joining instead of prior art methods that depend on homologous recombination. Additional optional features of the vectors include transposase sites that enable rapid swapping of genes and a selectable marker gene, e.g., blasticidin, which is advantageous because of its small size, its rapid killing of non-transformed cells, its function when formatted as a fusion protein, and its ability to kill bacteria and protozoans that can contaminate and damage the health of spirulina cultures.
[0124] As used herein ‘'spirulina” is synonymous with “Arthrospira.” In some embodiments, any species of spirulina can be utilized. Spirulina can grow in fresh water or salt water. In some embodiments, spirulina can be acquired from a culture collection source. Compositions of the present disclosure can comprise any one of the following species of spirulina: A. amethystine, A. ardissonei, A. argentina, A. balkrishnanii, A. baryana, A. boryana. A. braunii, A. breviarticulata, A. brevis, A. curta, A. desikacharyiensis, A. funiformis, A. fusiformis, A. ghannae, A. gigantean, A. gomontiana, A. gomontiana var. crassa, A. indica. A. jenneri var. platensis. A. jenneri Stizenberger, A. jenneri. purpurea, A. joshii, A. khannae, A. laxa, A. laxissima, A. laxissima, A. leopoliensis, A. major, A. margaritae, A. massartii, A. massartii var. indica, A. maxima, A. meneghiniana, A. miniata var. constricta, A. miniata, A. miniata f. acutissima, A. neapolitana. A. nordstedtii, A. oceanica, A. okensis, A. pellucida, A. platensis, A. platensis var. non-constricta, A. platensis f granulate, A. platensis f. minor, A. platensis var. tenuis, A. santannae, A. setchellii, A. skujae, A. spirulinoides f. tenuis, A. spirulinoides, A. subsalsa, A. subtilissima, A. tenuis, A. tenuissima, and A. versicolor. In some embodiments, a species of spirulina comprises Spirulina platensis. In some embodiments, a species of spirulina comprises Arthrospira platensis. Reference to a “native” or “nontransformed” spirulina refers to a spirulina strain that has not had an expression cassette introduced.
[0125] In some embodiments, a spirulina culture is axenic. The present invention effectively transforms axenic A. platensis and does not require bacterial contamination of the A. platensis cultures. This simplifies the protocol, reduces the risk of bacterial cross contamination of cultures, and allows A. platensis to be grown and studied without the laborious process of isolating A. platensis. The status of a culture, such as determining whether it is axenic or not, can be determined by way of microscopic examination and / or
[0126]
[0127] confirmed by negative results after cultivation. Use of axenic cultures, such as those in which only a single species, variety, or strain of organism is present and entirely free of all other contaminating organisms, are the preferred means of engineering cells as the presence of contaminants may affect growth and / or engineering of the target cell. While prior art methods utilize co-culture with other microorganisms to induce competence in the spirulina (e.g., US2024 / 0002481), the spirulina described herein may be produced axenically.
[0128] A native spirulina strain is contacted with an expression cassette. In certain embodiments, the spirulina and expression cassette are contacted with a quorum sensing molecule, also called an autoinducer, to stimulate DNA uptake by A. platensis. This can be used in combination with electroporation and cationic lipids for efficient transformation of A. platensis using non-homologous targeting vectors as described here. Quorum sensing molecules include acylated homoserine lactones (AHLs), a class of small neutral lipid molecules composed of a homoserine lactone ring with an acyl chain. Other quorum sensing molecules include autoinducing peptides, autoinducer 1. autoinducer 3, and autoinducer-2. See, e.g.„ Acet, O., Erdonmez, D., Acet, B O. et al. A-acyl homoserine lactone molecules assisted quorum sensing: effects consequences and monitoring of bacteria talking in real life. Arch Microbiol 203, 3739-3749 (2021).
[0129] https: / / doi.Org / 10.l 007 / s00203-021 -02381 -9. which is incorporated herein by reference.
[0130] The vectors utilized herein include an “expression cassette". The expression cassette includes at least a promoter operably linked to a sequence encoding a polypeptide of interest. The expression cassette can include one or more additional regulatory elements, such as an enhancer, polyadenylation site, etc. The expression cassette does not contain homology arms that are necessary for homologous recombination. Thus, in certain embodiments, the expression cassette contains less than lOObp having 95% or greater homologj7to a spirulina endogenous sequence. In certain embodiments, the expression cassette contains less than 200bp having 95% or greater homology7to a spirulina endogenous sequence. In certain embodiments, the expression cassette contains less than 300bp having 95% or greater homology to a spirulina endogenous sequence. In certain embodiments, the expression cassette contains less than 400bp having 95% or greater homology7to a spirulina endogenous sequence. In certain embodiments, the expression cassette contains less than 500bp having 95% or greater homology to a spirulina endogenous sequence. In certain embodiments, the expression cassette contains up to
[0131]
[0132] about 500bp having 95% or greater homology to a spirulina endogenous sequence. In certain embodiments, the expression cassette contains up to about 400bp having 95% or greater homology to a spirulina endogenous sequence. In certain embodiments, the expression cassette contains up to about 300bp having 95% or greater homology to a spirulina endogenous sequence. In certain embodiments, the expression cassette contains up to about 200bp having 95% or greater homology' to a spirulina endogenous sequence. In certain embodiments, the expression cassette contains up to about lOObp having 95% or greater homology to a spirulina endogenous sequence.
[0133] In certain embodiments, the expression cassette includes a strong promoter.
[0134] Various promoters useful herein are known in the art. In one embodiment, the promoter is the J23119 promoter. Other useful promoters include J23100, syn35 promoter, the lambda left promoter, the T5 promoter, the T7 promoter, and trc promoter.
[0135] In other embodiments, the expression cassette includes a regulatable promoter that permits controlled transcription in response to an exogenous or environmental signal. Suitable regulatable promoters include, without limitation, inducible and repressible prokaryotic systems such as lac promoters and derivatives thereof (e.g., lac. lacUV5, and hybrid tac or trc promoters) regulated by LacI and responsive to lactose analogs including IPTG; T7-based promoters under control of lac regulatory elements; arabinose-inducible promoters (e.g., PBAD) regulated by AraC; tetracycline-responsive promoters (e.g., tet promoters) regulated by TetR and inducible by tetracycline or doxycycline; rhamnose-inducible promoters (e.g., PrhaBAD); and promoters responsive to other small molecules, including cumate-, salicylate-, or benzoate-inducible systems. Additional regulatable promoters include environmentally responsive promoters such as heat shock promoters, oxidative stress-responsive promoters, quorum-sensing-regulated promoters, and metabolite-responsive systems.
[0136] In certain embodiments, the expression cassette may contain one or more recognition sites for site-specific recombinases, i.e., enzymes that can precisely cut and rejoin DNA. Examples include attP and attB sites, wherein the attP site is included in the vector. The attB site is then included in a construct that is used to swap the transgene in the expression cassette to be inserted into the spirulina. This provides for a simplified system of manipulation of spirulina, which is not possible with the prior art systems.
[0137] Various site-specific recombination systems are known in the art, and useful herein. Such systems include tyrosine and serine recombination systems. See, e.g., Li H,
[0138]
[0139] Sharp R, Rutherford K, Gupta K, Van Duyne GD. Serine Integrase attP Binding and Specificity. J Mol Biol. 2018 Oct 19;430(21):4401-4418. doi: I0.1016 / j.jmb.2018.09.007. Epub 2018 Sep 15. PMID: 30227134; PMCID: PMC6339855. which is incorporated herein by reference. In certain embodiments, such transposase sites are included in the transforming DNA to create landing pad strains of spirulina, in which the exogneous genetic elements can be replaced using co-transfection of appropriate donor plasmids and the Bxbl and / or pHIC31 transposase. See, e.g., Low, B.E., Hosur. V., Lesbirel, S. et al. Efficient targeted transgenesis of large donor DNA into multiple mouse genetic backgrounds using bacteriophage Bxbl integrase. Set Rep 12, 5424 (2022).
[0140]
[0141] >s / / dor 09445-w, which is incorporated herein by reference.
[0142] The expression cassette, in certain embodiments, includes a coding sequence for an antibiotic resistance gene which allows selection of transformants and protection against bacterial and protozoal contamination. In one embodiment, the expression cassette includes a blasticidin resistance gene (such as that included in SEQ ID NO: 1). In one embodiment, the expression cassette includes a hygromycin resistance gene (such as that included in SEQ ID NO: 2). Other antibiotic resistance genes include bla (ampicillin resistance), kanR or nptll (kanamycin resistance), tetA (tetracycline resistance), cat (chloramphenicol resistance), aadA (streptomycin / spectinomycin resistance), hph (hygromycin resistance), and ermC (ery thromycin resistance).
[0143] The antibiotic resistance gene may be expressed as a fusion protein with the polypeptide of interest, or separated from the ORF of the polypeptide using, e.g., a 2 A peptide cleavage site. Thus, the expression cassette may contain a 2A peptide or IRES coding sequence.
[0144] In certain embodiments, one or more restriction site domains flank the gene of interest to provide options to isolate the DNA from the vector prior to transformation and to provide the option to create different types of broken DNA ends to facilitate non- homologous end joining. In certain embodiments, the restriction sites include KHEX, which includes Kpnl, EcoRI, Hpal, and Xhol sites or BPEH, which includes BamHI, PstI, EcoRI, and Hpal sites). Numerous restriction enzyme sites are known, and include, without limitation, EcoRI, BamHI, Hindlll, Noth Xhol, PstI, Nhel, Sall, Smal, EcoRV, Hpal, and Kpnl, each recognizing specific DNA sequences and producing either sticky or blunt ends.
[0145]
[0146] In addition, the expression cassette may contain one or more tags, such as those used for detection of the expressed protein (e.g., ALFA-tag, HIS-tag, HA-tag, etc.). The expression cassette can include a ribosome binding site.
[0147] The expression cassette contains a sequence encoding a polypeptide of interest. In certain embodiments, the polypeptide is a stimulator of mucosal immunity. Spirulina is commonly eaten as a food. When eaten, spirulina passes into the intestine, where digestion releases proteins that are contained within the spirulina cells. Spirulina strains that produce monoclonal antibodies or a viral-like-particle vaccine have demonstrated that therapeutically relevant amounts of these proteins can be delivered simply by feeding spirulina to a subject [1, 2]. The present invention builds on this, and in certain embodiments, the spirulina are engineered to express bacterial proteins that are potent simulators of mucosal immunity. The basis of their ability to stimulate mucosal immunity likely rests on their normal function, which is to infect mucosal tissues, and the host immune mechanisms that have evolved to combat their pathogenic activity.
[0148] Table 1, below, shows production vectors and constructs used to generate recombinant spirulina which are each embodiments of the invention.
[0149]
[0150] Category SEQ Name ORF Purpose Description
[0151] amino
[0152] acids
[0153] Vectors 1 YFP Blast 370 YFP Blast comonomeric hyperfolder YFP selection fused to Blast for selection 2 YFP Hygro 510 YFP Hygro comonomeric hyperfolder YFP selection fused to hygro for selection
[0154] Rotavirus VHH ARP1 3 ARP1 ALFA E3 345 Rotavirus ARP1, alfa, E3 dimerization treatment domain, T2A cleavage of blast 4 ARPl_ALFA_E3_mhYFP 585 Rotavirus ARP1, alfa, E3 dimerization treatment domain, T2A cleavage of mhYFP-blast
[0155] 5 ARP1 ALFA dLANYFP 530 Rotavirus ARP1, alfa, dimeric YFP,T2A treatment cleavage of blast
[0156] 6 ARPI Fc 514 Rotavirus ARP1, Fc tag,T2A cleavage of treatment blast
[0157] Rotavirus scFv mAb 41 7 mAb 41 ALFA E3 474 Rotavirus mAb 41, alfa, E3 dimerization treatment domain, T2A cleavage of blast
[0158]
[0159]
[0160] 8 mAb 41_ALFA_E3_mhYFP 713 Rotavirus mAb 41, alfa, E3 dimerization treatment domain, T2A cleavage of mhYFP-blast
[0161] 9 mAb 41 ALFA dLANYFP 658 Rotavirus mAb 41, alfa, dimeric YFP, T2A treatment cleavage of blast
[0162] 10 mAb 41_Fc 642 Rotavirus mAb 41, Fc tag,T2A cleavage of treatment blast
[0163] Clostridial vaccines 11 Perf_ALFA:T2A Blast 293 Chicken NE C. perfringens C-terminal vaccine / Mucosal domain, ALFA tagged, T2A adjuvant cleavage of blast
[0164] 12 HWL-Del blast 514 Chicken NE Alfa toxin-NetB fusion (deleted vaccine multimerization domain)
[0165] ALFA T2A Blast
[0166] 13 HWLblast 600 Chicken NE Alfa toxin-NetB fusion (entire vaccine NetB) ALFA:T2A Blast
[0167] 14 Perf mini H3 570 Chicken NE and Influenza M2e_H3 mini stalk Influenza (cross protective)
[0168]
[0169]
[0170] 15 BoNTD 736 Mucosal adjuvant BoNT serotype D: C-terminal, non neuronal binding, ALFA tagged, T2A cleavage of blast
[0171] Enterotoxins / Poliovirus 16 HL ETB ALFA T2A 278 ETEC vaccine Heat labile enterotoxin B chain Blast, dna from ETEC
[0172] 17 CTxB_ALFA_T2A Blast 253 Cholera vaccine Cholera toxin B subunit
[0173] 18 BC loop_HL_ETB_T2A 291 ETEC and Polio HL enterotoxin with 2 BC loop Blast, dna vaccine sequences
[0174] 19 BC loop_CTxB_T2A Blast 266 Cholera and Polio CTxB with 2 BC loop sequences vaccine
[0175]
[0176]
[0177] In addition to the exemplified constructs, alternative embodiments are provided wherein the coding sequences share at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with ORF identified herein. Alternative embodiments are provided wherein the coding sequences share less than 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with ORF identified herein. For example, the ORFs may be codon optimized for expression in the desired organism.
[0178] A diverse literature has established that the C-terminal domains (CTDs) of clostridial toxins can stimulate mucosal immunity, including IgG and IgA responses to the toxin domains as well as to proteins fused to the domains. The C. perfringens alpha toxin CTD binds to claudin 4, a tight junction protein, and thereby translocates via M-cells into mucosal lymphoid follicles (Peyer's patches), where it induces mucosal immunity that includes expression of IgA and IgG |3J. Immunity is also directed at polypeptides fused to the CTD [3], C. botulinum and C. tetani CTDs also induce mucosal immunity, for example, when administered orally or intranasally. The spirulina strains described here can be administered to any mucosal site, including orally or intranasally.
[0179] In various embodiments, the disclosed spirulina strains express C. perfringens CTD, alone (e.g., FIG. 11 , SEQ ID NO: 11 ) or fused to a second protein of interest. In one embodiment, the CTD is fused to the C. perfringens NetB protein (e.g., FIG. 12-13, SEQ ID NO: 12 and 13), which can be used as a vaccine to prevent necrotic enteritis in chickens [4], Necrotic enteritis is a fatal disease initiated by overgrowth of C. perfringens, followed by a cocci diosis superinfection, which is estimated to cost the US poultry industry $6 billion annually.
[0180] Another disclosed strain expresses the C. perfringens CTD fused to recombinant influenza vaccine which can be used to prevent avian influenza infection (H5N1) as ell as provide protection against necrotic enteritis. FIG. 14, SEQ ID NO: 14. See, e.g., Kalaiyarasu S, Bhatia S, Mishra N, Senthil Kumar D, Kumar M, Sood R, Rajukumar K, Ponnusamy B, Desai D, Singh VP. Elicitation of Highly Pathogenic Avian Influenza H5N1 M2e and HA2-Specific Humoral and Cell-Mediated Immune Response in Chicken Following Immunization With Recombinant M2e-HA2 Fusion Protein. Front Vet Sci. 2021 Feb 5;7:571999. doi: 10.3389 / fvets.2020.571999. PMID: 33614753; PMCID:
[0181] PMC7892607 which is incorporated herein by reference. We are currently in the midst of an epizootic H5N1 infection in US poultry [5], which has infected over 1000 flocks since early 2022, approximately 100 million birds, costing over $1 billion in federal
[0182]
[0183] expenditures for disease control and insurance payments. This strain can be administered in water or food, for 2-3 doses, administered ~2 weeks apart.
[0184] Another disclosed strain expresses the C. perfringens CTD fused to an endoplasmic reticulum retention sequence. In certain embodiments, the ER-retention sequence is KDEL. This strain is useful for treatment of inflammatory' bowel disease and other related conditions. The classical ER retention signal for soluble luminal proteins is the C-terminal KDEL (Lys-Asp-Glu-Leu) sequence. Membrane-bound ER proteins often have a C-terminal KKXX (where X can be any amino acid) or similar sequence.
[0185] Spirulina is also disclosed that expresses C. botulinum from serotype D that has been altered to prevent interaction of the toxin with neurons (FIG. 15, SEQ ID NO: 15). The botulinum CTD can be used to vaccinate humans or animals against botulinum toxin; a botulinum CTD can be used as a mucosal vaccine adjuvant when fused to an antigenic polypeptide.
[0186] In another embodiment, spirulina strains suitable for use as vaccines against cholera and enterotoxigenic E. coli (ETEC), which express cholera toxin B (FIG. 17) or the heat labile enterotoxin B subunit (e.g., FIG. 16) are provided herein. Another disclosed strain expresses the cholera toxin B subunit fused to an endoplasmic reticulum retention sequence. In certain embodiments, the ER-retention sequence is KDEL.
[0187] In another embodiment, spirulina strains are provided suitable for use as vaccines against poliovirus, specifically type II poliovirus, the serotype that comprises the majority’ of currently circulating vaccine derived poliovirus (cVDPV) strains [6], E.g., FIG. 18 and 19.
[0188] In certain embodiments, the vaccine proteins expressed by the spirulina are fusions of the highly conserved BC loop of type II (Lansing), which are known to induce cholera and enterotoxigenic E. coli (ETEC), which express cholera toxin B or the heat labile enterotoxin B subunit. The BC loop can be attached to either the N-terminal or C-terminal domain of the CTB or HLEB polypeptides, which are pentameric, to create an immunogenic molecule containing 5 or 10 copies of the BC loop polypeptide. These spirulina can be produced and inexpensively administered to help control spread of cVDPVs. Further, these vaccines provide protection from cholera or ETEC as well as poliovirus.
[0189] In certain embodiments, spirulina strains suitable for treatment of rotavirus infection are provided. Described herein are four examples for each of two antibodies, the
[0190]
[0191] VHH ARP1 [9] (FIGs. 3-6, SEQ ID NO:s 3-6) and an scFV modeled after mAb 41
[0014] (FIGs. 7-10, SEQ ID NO:s 7-10). which express the antibodies in dimeric forms. In general, these inventions all benefit from the low cost and efficiency of growing and administering antibodies and vaccine antigens via spirulina. For these reasons, spirulina is ideal for use to prevent enteric colitis and influenza in poultry flocks (and other agricultural animals). For treatment of human populations to prevent infectious diseases spirulina has multiple advantages, including that it can be produced inexpensively and administered as a food or drink, to prevent cholera, ETEC, and botulinum. Spirulina expressed monoclonal antibodies can completely change the paradigm for delivery of therapeutic antibodies to individuals in resource poor countries, and the provision of spirulina expressing anti-rotavirus antibodies can help solve the problem of low efficacy of the oral rotavirus vaccines in low- and middle-income countries. Lastly, the proteins utilized here are powerful mucosal adjuvants and can be delivered as fusion proteins to provide mucosal immunity against any pathogen molecule to which they can be fused.
[0192] In another aspect, the DNA vectors introduced here are used to express monoclonal antibodies, in particular single chain antibody molecules, for example. scFv and VHH antibodies. Two monoclonal antibodies are exemplified herein. The VHH ARP1 binds to VP6 and has shown efficacy in human and animal models [9, 10, 12], The mAh 41 binds rotavirus VP8 and part of VP5*
[0014] has shown efficacy in the suckling mouse model
[0015] , The antibodies are provided in 4 dimeric formats: (1) fused to an IgG Fc domain, (2) fused to a p53 dimerization domain (note the domain is a mutated tetramerization domain), (3) fused to p53 dimerization domain linked to a monomeric hyperfolder yellow fluorescent protein tag (YFP)
[0016] , and (4) fused to a dimeric YFP (dLANYFP)
[0017] , In some embodiments, the present disclosure provides a recombinant spirulina cell created using the methods disclosed herein. In some embodiments, the present disclosure provides a population comprising recombinant spirulina cells created using the methods disclosed herein.
[0193] The methods of making recombinant spirulina described herein include contacting a native spirulina strain with an expression cassette and, optionally, a quorum sensing molecule. In certain embodiments, the native spirulina strain is axenic. In certain embodiments, another method or composition for inducing competence in the spirulina is utilized, such as electroporation or a cationic lipid.
[0194]
[0195] Methods of Treatment
[0196] Provided herein are methods that utilize pharmaceutical compositions that include the engineered spirulina described herein. In one aspect, a method of inducing mucosal immunity in a subject in need thereof is provided. The method includes administering an engineered spirulina as described herein.
[0197] Here are disclosed spirulina strains that express the cholera toxin B (CTB) and the heat labile enterotoxin B subunit (HLEB), which are useful as mucosal vaccines for the prevention of cholera and ETEC diarrhea, respectively.
[0198] The cholera toxin B (CTB) and the heat labile enterotoxin B subunit (HLEB) are potent stimulators of mucosal immunity. Each is a short polypeptide that exists in nature as a pentameric structure combined with a pathogenic, catalytic molecule. Expressed by the bacterium Vibrio cholerae, CTB combines with cholera toxin A, which activates adenylate cyclase to cause the diarrhea that characterizes cholera. In strains of enterotoxigenic E. coli (ETEC) HLEB similarly combines with catalytic toxins to cause diarrhea. CTB and HLEB bind to mucosal epithelia, where they are transported and induce Thl7+ T cells and expression of IgA and IgG. CTB especially has been used as an adjuvant for mucosal vaccination. Unlike clostridial toxins, CTB and HLEB exist in pentameric forms, and can therefore present antigens in a multimeric format to enhance the immune response, especially when small polypeptide antigens are implemented.
[0199] Also disclosed are strains that express CTB and HLEB conjugated to the BC loop polypeptide of type II poliovirus. The BC loop polypeptide expresses a linear epitope that is the primary target of antibodies that neutralize type II PV. The disclosed strains have the polypeptide conjugated to the N-terminal and C-terminal domains of the toxins, which presents 10 copies of each antigen per pentamer structure. These strains are useful as mucosal vaccines for the prevention of poliovirus.
[0200] A lack of mucosal immunity against type II in parts of the world where oral vaccination has historically been standard (due to the discontinuation of regular use of OPV2) has allowed widespread distribution of circulating type II vaccine-derived polioviruses in the developing world [6], The almost complete lack of mucosal immunity in the developed world means that cVDPVs may spread undetected until they cause paralysis in an unvaccinated child. The vaccine strains of the present invention can be used to safely provide mucosal immunity against type II cVDPVs, to help combat the global resurgence of polio, while also protecting children from cholera or ETEC.
[0201]
[0202] In another aspect, the DNA vectors introduced here are used to express monoclonal antibodies, in particular single chain antibody molecules, for example. scFv and VHH antibodies. In certain embodiments, the engineered spirulina strains described herein are useful in treating and preventing rotavirus infection. Live attenuated rotavirus vaccines exist. These can greatly reduce the incidence of fatal diarrhea, but they substantially underperform in many low- to middle-income countries, so that the morbidity and mortality of rotavirus continues to be a serious challenge [7],
[0203] Multiple studies (including human trials) have shown that antibodies can reduce rotavirus disease severity7when administered orally [8-13], However, monoclonal antibody production and purification is an extremely expensive process and not well-matched to providing antibody treatments economically. Monoclonal antibodies delivered by spirulina will protect from rotavirus diarrhea, and they have been effective in a mouse model of Campylobacter jejunum infection [1], Monoclonal antibodies made in spirulina, however, could be administered by feeding the subject intact spirulina. Spirulina manufacture is also very inexpensive, as it only requires salty, alkaline water, aeration, and sunlight. A spirulina monoclonal antibody product could be produced in low resource settings for pennies per dose and is therefore of interest to funding agencies supporting work to treat patients in those settings.
[0204] In another aspect, spirulina strains are provided for use as mucosal vaccines for necrotic enteritis. As described herein, certain engineered spirulina strains express the CTD in combination with NetB, a key determinant of pathogenicity necrotic enteritis. See, US20230142894A1, Roland et al., Vaccine for prevention of necrotic enteritis in poultry, which is incorporated herein by reference.
[0205] In another aspect, spirulina strains are provided for use as mucosal vaccines for avian influenza and necrotic enteritis. Strains express a C. perfringens CTD protein known to strongly induce mucosal immunity fused to a broad spectrum mini-stalk influenza vaccine that is combined with avian M2e antigens and known to provide heterotypic immunity. See, e.g, WO 2023 / 220614 A2, Recombinant subunit based universal influenza and respiratory virus vaccines, which is incorporated herein by reference.
[0206] In another aspect, spirulina strains are provided for use as mucosal vaccines for botulinum infection. Suitable spirulina strains include those express the seroty pe D toxin c-terminal domain (FIG. 15).
[0207]
[0208] The spirulina compositions described herein are administered to a subject to treat or prevent a condition. By “administering” or “route of administration” is meant delivery of a therapy described herein, with or without a pharmaceutical carrier or excipient, of the subject. Routes of administration may be combined, if desired. In some embodiments, the administration is repeated periodically. Any delivery' route that leads to contact with the mucosa of the subject is permissible, including oral and intranasal delivery'.
[0209] In another embodiment, the composition includes a carrier, diluent, excipient and / or adjuvant. Suitable carriers may be readily selected by one of skill in the art in view of the indication for which the transfer virus is directed. For example, one suitable carrier includes saline, which may be formulated with a variety of buffering solutions (e.g., phosphate buffered saline).
[0210] Dosage of the composition will depend, among other things, on the condition of the subject, the particular indication being treated, the route of administration, the formulation of the therapeutic agent employed, etc. For example, the dosage will ty pically be about 1 to 10 grams per kilogram subject body weight. The terms “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of the spirulina being administered that would be expected to relieve to some extent one or more of the symptoms of the disease or condition being treated. It is understood that “an effective amount” or “a therapeutically effective amount” varies, in some embodiments, from subject to subject, due to variation in metabolism of the compound administered, age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician.
[0211] The compositions described herein may be administered on a regimen as determined by a physician. In certain embodiments, the compositions are administered more than once per day. In other embodiments, the compositions are administered daily. In other embodiments, the compositions are administered 2, 3, 4, 5, 6, or more times per week. In other embodiments, the compositions are administered 1, 2, 3, 4, 5 or more times per month. In other embodiments, the compositions are administered every' 2, 3. 4, 5, 6, 7, 8, 9. or 10 weeks. In other embodiments, the compositions are administered 1, 2, 3, 4. 5, 6, 7, 8, 9, 10, 11, 12 or more times per year.
[0212] The compositions described herein may optionally be administered in conjunction with other, different, therapeutic agents useful in the treatment of the disorders or conditions described herein.
[0213]
[0214] As used herein, “disease”, “disorder” and “condition” are used interchangeably, to indicate an abnormal state in a subject. In one embodiment, the disease is retinopathy, such as diabetic retinopathy. In another embodiment, the disease is glaucoma.
[0215] While various embodiments in the specification are presented using “comprising” language, under various circumstances, a related embodiment is also described using “consisting of’ or “consisting essentially of’ language. “Comprising” is a term meaning inclusive of other components or method steps. When “comprising” is used, it is to be understood that related embodiments include descriptions using the “consisting of’ terminology7, which excludes other components or method steps, and “consisting essentially of’ terminology, which excludes any components or method steps that substantially change the nature of the embodiment or invention.
[0216] The terms “a” or “an” refers to one or more. For example, "an expression cassette” is understood to represent one or more such cassettes. As such, the terms “a” (or “an”), “one or more,” and “at least one” are used interchangeably herein.
[0217] As used herein, the term “about” means a variability of plus or minus 10 % from the reference given, unless otherwise specified.
[0218] Preferred Embodiments
[0219] 1. A recombinant spirulina comprising an expression cassette, the expression cassette comprising a nucleic acid comprising an exogenous promoter sequence operably linked to a sequence encoding a polypeptide.
[0220] 2. A recombinant spirulina of embodiment 1 in which the expression cassette was incorporated into the genome using processes independent of homologous recombination.
[0221] 3. The recombinant spirulina of embodiment 1 or 2, wherein the expression cassette does not contain an endogenous spirulina gene and / or wherein the homologous domains within the expression cassette have not undergone homologous recombination during their incorporation into the spirulina genome.
[0222] 4. The recombinant spirulina of any one of embodiments 1 to 3, wherein the expression cassette contains one or more recognition sequences capable of mediating sitespecific recombination.
[0223] 5. The recombinant spirulina of any one of embodiments 1 to 4, wherein the exogenous promoter sequence is a high efficiency heterologous promoter sequence.
[0224]
[0225] optionally wherein the heterologous promoter sequence comprises a J23119 promoter sequence.
[0226] 6. A recombinant spirulina of any one of embodiments 1 to 5, in which the polypeptide is capable of inducing a mucosal immune response.
[0227] 7. The recombinant spirulina of any one of embodiments 1 to 6, wherein the expression cassette encodes a polypeptide sequence of interest.
[0228] 8. The recombinant spirulina of embodiment 7, wherein the polypeptide sequence of interest provides resistance to the toxic effects of blasticidin.
[0229] 9. The recombinant spirulina of embodiment 7, wherein the polypeptide sequence of interest provides resistance to the toxic effects of hygromycin.
[0230] 10. The recombinant spirulina of any one of embodiments 1 to 9, wherein the polypeptide sequence of interest is an antibody or a vaccine (e.g. rotavirus or poliovirus).
[0231] 11. The recombinant spirulina of any one of embodiments 1 to 10, in which the polypeptide is a Clostridium toxin or a fusion protein comprising a Clostridium toxin. 12. The recombinant spirulina of embodiment 11, in which the clostridial toxin is derived from C. botulinum. C. perfringens. or C. difficile.
[0232] 13. The recombinant spirulina of embodiment 11 or 12, in which the clostridial toxin is fused to the NetB toxin, influenza hemagglutinin (HA), or a fragment thereof.
[0233] 14. The recombinant spirulina of any one of embodiments 1 to 10, in which the polypeptide is a cholera toxin or a fusion protein comprising a cholera toxin.
[0234] 15. The recombinant spirulina of embodiment 14, in which the cholera toxin is the cholera toxin B subunit.
[0235] 16. The recombinant spirulina of embodiment 14, in which the cholera toxin is the cholera toxin B subunit fused to a poliovirus antigen (BC loop polypeptide).
[0236] 17. The recombinant spirulina of embodiment 14, in which the cholera toxin is the cholera toxin B subunit expressed with a c-terminal KDEL endoplasmic reticulum retention sequence comprising the amino acids Lys-Asp-Glu-Leu.
[0237] 18. The recombinant spirulina of any one of embodiments 1 to 10. in which the
[0238]
[0239] polypeptide is an E. coli heat labile enterotoxin.
[0240] 19. The recombinant spirulina of embodiment 18, in which the E. coli heat labile enterotoxin is the enterotoxin B subunit.
[0241] 20. The recombinant spirulina of embodiment 18, in which the E. coli heat labile enterotoxin is the double mutant heat-labile enterotoxin B, specifically LT(R192G / L211A).
[0242] 21. A method of generating the strain of spirulina of any one of embodiments 1 to 20 comprising contacting a native spirulina with the expression cassette.
[0243] 22. The method of embodiment 21, wherein the native spirulina is in an axenic population.
[0244] 23. The method of embodiment 21 or 22, further comprising treating with AHL (or other quorum sensing molecule).
[0245] 24. The method of any one of embodiments 21-23, wherein the expression cassette comprises an antibiotic resistance gene, further comprising contacting the spirulina with the antibiotic (Blasticidin, Hygromycin B).
[0246] 25. The method of one of embodiments 21-24, further comprising performing electroporation or contacting the spirulina and / or expression cassette with cationic lipids that promote transformation of the spirulina.
[0247] 26. A method of generating a recombinant spirulina having a genome comprising an expression cassette, the method comprising:
[0248] a) contacting spirulina with a donor nucleic acid comprising a DNA sequence flanked by recombinase recognition sites,
[0249] b) contacting spirulina with nucleic acids encoding one or more recombinases, thereby effecting a swap of ectopic DNA sequences within the genome with donor DNA sequences.
[0250] 27. The recombinant spirulina or method of any one of embodiments 1 to 26. wherein the expression cassette has attP sites.
[0251] 28. The recombinant spirulina or method of embodiment 27, wherein the attP sites are specific for the transposases BxBl and PhiC21.
[0252]
[0253] 29. The method of any one of embodiments 21-28, further comprising co-transfection with plasmids expressing transposases.
[0254] 30. A method of mucosal administration of a protein of interest, the method comprising administering a recombinant spiruhna comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding the protein of interest.
[0255] 31. A method of mucosal vaccination of a subject with a protein of interest, the method comprising administering a recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding the protein of interest.
[0256] 32. A method of mucosal vaccination of a subject with a protein of interest, in which the protein is capable of specific interaction with mucosal microfold cells, the method comprising administering a recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding the protein of interest, thereby inducing a mucosal specific (IgA) immune response.
[0257] 33. The method of any one of embodiments 30-32 wherein the protein of interest comprises a Clostridium toxin or a fusion protein comprising a Clostridium toxin.
[0258] 34. The recombinant spirulina or method of any one of embodiments 1 to 33 wherein the expression cassette lacks homology or lacks flanking sequences with homology to spirulina genome.
[0259] 35. The recombinant spirulina or method of any one of embodiments 1 to 34 wherein the expression cassette does not contain an endogenous spirulina gene or a sequence sharing greater than 95% identity with a spiruhna gene.
[0260] 36. The recombinant spirulina or method of any one of embodiments 1 to 35 wherein the recombinant spirulina has a full-complement of genes expressed by a parental strain and / or the expression cassette does not disrupt expression of an endogenous spirulina gene locus.
[0261] 37. A recombinant spiruhna produced according to the method of any one of embodiments 21 to 29.
[0262]
[0263] 38. A method of inducing a mucosal immune response in a subject, the method comprising administering the recombinant spirulina of any one of embodiments 1 to 37 to the subject, optionally wherein the administration is via an oral route.
[0264] 39. A recombinant spirulina comprising an expression cassette, the expression cassette comprising a nucleic acid comprising an exogenous promoter operably linked to a sequence encoding a cholera toxin or a fusion protein comprising a cholera toxin.
[0265] 40. A recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding a heat-labile toxin or a fusion protein comprising a heat-labile toxin.
[0266] 41. The recombinant spirulina of embodiment 39 or 40, wherein the fusion protein comprises a poliovirus vpl or fragment thereof.
[0267] Examples
[0268] The following examples disclose specific embodiments of recombinant NMDA antibodies and methods of use thereof. These examples should be construed to encompass any and all variations that become evident as a result of the teaching provided herein.
[0269] Example 1: Preparation of spirulina strains
[0270] The DNAs of the present invention can be introduced into axenic spirulina using electroporation following standard protocols [1], The DNAs are maintained in E. coli subcloned into the arabinose inducible plasmid, pCCl. Prior to electroporation, the insert DNA can be cleaved from the vector DNA, which creates recombinogenic double stranded breaks. Multiple cut site domains are included 5' to the cloned gene (5' KHEX, which includes Kpnl, EcoRI, Hpal, and XhoT sites) and 3' (3' BPEH, which includes BamHI, PstI, EcoRI, and Hpal sites). When cut, these enzymes give recombinogenic 5' overhangs (Kpnl, PstI), 3' overhangs (BamHI, EcoRI, Xhol) or blunt ends (Hpal). DNA inserts are isolated using agarose gel electrophoresis and purified using Qiagen spin columns. The DNA is mixed with axenic spirulina growing at log phase, suspended in hypo-osmotic buffer, and electorporated using a Bio-Rad Gene Pulser. The cells are allowed to rest for 15 minutes, then washed and suspended in Zarrouk's growth medium. After 3 additional days, cells are exposed to blasticidin (about Ipg / ml) or hygromycin (about 6pg / ml) as
[0271]
[0272] indicated. Cells are maintained in sunlight and cultured to isolate drug resistant transformants.
[0273] Example 2:
[0274] Infectious diseases are a major challenge to the poultry' industry. Highly pathogenic avian influenza (HP Al, aka "bird flu") is one of the most serious threats, because even a single detection can force a farm to destroy an entire flock. Conventional influenza vaccine strategies are not suitable for use in chicken flocks because they are expensive, must be given by injection, and may fail to adequately protect against H5 or H7 strains that may be circulating in the future. An inexpensive oral vaccine strategy is needed to protect chicken flocks from epidemic HP Al.
[0275] Necrotic enteritis (NE) is one of the most serious diseases of broiler chickens, with global industry losses estimated in the multi-billion-dollar range each year due to slower grow th, poorer feed conversion, higher mortality7, and increased treatment and processing costs. A live Salmonella-based vaccine (AVERT NE) is useful, but it is a live bacterium that is expensive and must be sprayed onto young birds, which requires special handling and bird isolation. An oral supplement that is safe and inexpensive, and can be simply added to water or feed, would transform the landscape of NE prevention.
[0276] Described herein is a proprietary7platform that converts spirulina (Arthrospira platensis) into safe, effective, and nutritious oral vaccines. Spirulina is modified to express non-toxic proteins, and then dried, ground, and administered as a nutritional supplement in food or drink. The natural process of food digestion releases the proteins in the intestine, where they educate the intestinal immune system and thereby provide life-long protective immunity.
[0277] The inventors use this platform to produce spirulina to prevent necrotic enteritis (NE) and highly pathogenic avian influenza (HP Al). Spirulina is an ideal vector for poultry vaccination because it is a "superfood," a nutrient-dense whole foods packed with protein (55-70%), antioxidants, fiber, and healthy fats that is widely consumed by humans and animals. Adding spirulina to the diet of broiler chickens increases weight gain, strengthens the immune system, and improves overall health. Spirulina also helps chickens cope better with stress, such as heat or infections. Chickens readily consume spirulina in their feed or water, so implementing the oral immunization in farm and backyard settings will not require special handling or isolation. The anti-HPAI spirulina is specifically
[0278]
[0279] intended for use in chickens. However, it is also useful to immunize swine. This is important because swine and birds are "‘stepping-stone” hosts between wild birds and people. When a pig is simultaneously infected by avian and human influenza strains, new hybrid viruses will be produced, and a virus arises that can spread easily from person to person, it can trigger a human influenza pandemic, as happened with the 1957, 1968, and 2009 pandemics.
[0280] Example 3: Constructs for the expression of poliovirus VLPs (virus like particles) in A. platensis.
[0281] Three different DNA plasmids were synthesized by Genscript to express poliovirus capsid proteins with either wild type or two different sets of mutations identified by others that stabilize the VLPs in an immunogenic conformation [1, 2], The capsid proteins were expressed in a split-configuration for protease free production of VLPs taken directly from [3], except with the substitution of regulatory sequences active in A. platensis. The prototype construct was inserted into a pCCl -derived plasmid (single copy number, with plasmid amplification inducible by arabinose).
[0282] The complete plasmid with the wild type MEF-1 sequences MEFl_30_l_v2SM_WT is shown in Genbank text format (FIG. 20 and 45). Notable features include the N-terminal KHEX and the C-terminal BPEH domains that contain restriction sites for the generation of different recombinogenic ends prior to transformation, a gene encoding a fusion protein between a monomeric hyperfolder YFP and the hygromycin phosphotransferase protein, and flanking transposase target sites Bxbl attP and phi-C3 attP. DNA sequences specific for expression of poliovirus VLPs include a synthetic J23119 promoter driving expression of MEF-1 VP3 and MEF-1 VP2, which are separated by a T2A ribosome skipping sequence, regulatory sequences driving expression of the MEF-1 VP1 derived from the cpcA promoter from A. platensis, and a synthetic terminator sequence BBa_BB1006. Insert sequences only are shown in the Genbank files for MEF1 30 1 v2SM FOX (FIG. 21 and 46) and MEFI 30 I v2SM BLUE (FIG. 22 and 47). The DNA plasmids were obtained from Genscript as glycerol stocks in the EPI300 E. coli. Plasmid DNAs were prepared using standard methods following arabinose induction.
[0283]
[0284] EXAMPLE 4: constructs for the expression of cholera toxin B (CTXB) fusion proteins in A. platensis.
[0285] Two different DNA plasmids were synthesized by Genscript to express CTXB fusion proteins. The sequence is shown as a full length plasmid in the Genbank text file format, CTXB BC SEKDEL (FIG. 24 and 49). The prototype construct was inserted into a pCCl -derived plasmid (single copy number, with plasmid amplification inducible by arabinose). Notable features include the N-terminal KHEX and the C-terminal BPEH domains that contain restriction sites for the generation of different recombinogenic ends prior to transformation, a gene encoding a fusion protein between a monomeric hyperfolder YFP and the hygromycin phosphotransferase protein, and flanking transposase target sites Bxbl attP and phi-C3 attP. The CTXB fusion protein expressed by this construct contains a N-termina VP-1 BC loop polypeptide from poliovirus Lansing, the CTXB protein, an ALFA tag [ Gotzke H, Kilisch M, Martinez-Carranza M, Sograte-Idrissi S, Rajavel A, Schlichthaerle T, et al. The ALFA-tag is a highly versatile tool for nanobody -based bioscience applications. Nat Commun. 2019;I0(l):4403. Epub 20190927. doi: 10.1038 / s41467-019-12301-7. PubMed PMID: 31562305; PubMed Central PMCID: PMCPMC6764986], a second BC loop polypeptide, and an endoplasmic reticulum retention sequence (SEKDEL) [ Cela I, Dufrusine B, Rossi C, Luini A, De Laurenzi V, Federici L, et al. KDEL Receptors: Pathophysiological Functions, Therapeutic Options, and Biotechnological Opportunities. Biomedicines. 2022; 10(6). Epub 20220525. doi: 10.3390 / biomedicinesl0061234. PubMed PMID: 35740256; PubMed Central PMCID: PMCPMC9220330], A second plasmid was produced that contained a fusion protein that did not contain the BC loop polypeptides, CTXB SEKDEL (FIG. 23 and 48). The DNA plasmids were obtained from Genscript as glycerol stocks in the EPI300 E. coli. Plasmid DNAs were prepared using standard methods following arabinose induction.
[0286] EXAMPLE 5. Transformation of axenic A. platensis by electroporation.
[0287] Axenic (UTEX 3086) was purchased from UTEX Culture Collection at the University' of Texas, Austin, TX and cultured in flasks on orbital shakers at 100-150 rpm and under controlled conditions including: 75-85°F temperature, luminated with a mixture of natural and artificial light with an intensity of 213-313 lumens per square foot, with a light cycle of sunrise / sunset. A. platensis growth was monitored by measuring optical density7at 680-750 nm. Fresh medium was added when the culture density' reached 1-1.2
[0288]
[0289] OD. The appropriate volume of Spirulina needed for transformation was calculated using the following equation:
[0290] (40 id X (number of transformations) X 25)
[0291] 1000 pl / ml
[0292] The 4. platensis was centrifuged at 2000xg (3000-3500 rpm on Beckman Coulter 6R centrifuge) for 45 min at 4°C. The 4. platensis was then washed 3 times with 1 mM cold HEPES buffer pld 7.2-8.0 and centrifuged at 2000xg for 45 min at 4°C. The pellets were resuspended in cold HEPES buffer, with a goal of achieving a total transformation volume of 45-50 pl. The DNA used for transformation included MEF1_3O_1_V2SM_BLUE (FIG. 22 and 47). CTXB SEKDEL (FIG. 23 and 48), CTXB BC SEKDEL(FIG. 24 and 49) and did not contain regions homologous to A. platensis genomic DNA and was digested with EcoRI prior to use in the transformation.
[0293] We combined 500 ng plasmid DNA with the A. platensis in a 0.2 cm cuvette and incubated the mixture on ice for 10 min. A. platensis was electroporated with Bio-Rad Pulser Electroporation system Gemini BV using these conditions: 200 ohms, 4kv / cm. 125pFD and 5ms. Electroporated A. platensis was recovered from the cuvette with medium and transferred to 1.5 ml Eppendorf tubes containing 960 pl Zarrouk medium. Transformed A. platensis was then plated in 96 well plates at lOOpl / well and incubated in partial darkness in a drawer for 2-3 days. On day 3, transformed A. platensis was selected with an appropriate dose of antibiotics. We used 2.5pg / ml Spectinomycin, 6pg / ml Hygromycin B and Ipg / ml Blasticidin, depending on the selectable marker gene within the DNA construct. The selection dose was increased gradually after 20 days. A. platensis was supplemented twice a week with modified Zarrouk medium containing antibiotics and split 1:2 two to three times. Transformed A. platensis was then moved from 96 well plates to successive expansion into 48 well, 24 well, and 6 well plates before transferring to 25 ml flasks in 10 ml.
[0294] EXAMPLE 6. Transformation of axenic A. platensis by electroporation using cationic lipids.
[0295] Axenic (UTEX 3086) was purchased from UTEX Culture Collection at the University of Texas, Austin, TX and cultured in flasks on orbital shakers at 100-150 rpm and under controlled conditions including: 75-85°F temperature, luminated with a mixture
[0296]
[0297] of natural and artificial light with an intensity of 213-313 lumens per square foot, with a light cycle of sunrise / sunset.
[0298] A. platensis growth was monitored by measuring optical density at 680-750 nm. Fresh medium was added when the culture density reached 1-1.2 OD. The appropriate volume of Spirulina needed for transformation was calculated using the following equation:
[0299] (40 ul X (number of transformations) X 25)
[0300] 1000 pl / ml
[0301] The A. platensis was centrifuged at 2000xg (3000-3500 rpm on Beckman Coulter 6R centrifuge) for 45 min at 4°C. The A. platensis was then washed 3 times with 1 mM cold HEPES buffer pH 7.2-8.0 and centrifuged at 2000xg for 45 min at 4°C. The pellets were resuspended in cold HEPES buffer, with a goal of achieving a total transformation volume of 45-50 pl. The DNA used for transformation included MEF1_3O_1_V2SM_BLUE (FIG. 22 and 47), CTXB SEKDEL (FIG. 23 and 48), CTXB_BC_SEKDEL (FIG. 24 and 49) and did not contain regions homologous tort. platensis genomic DNA and was digested with EcoRI prior to use in the transformation.
[0302] We combined 500 ng plasmid per transfection with 3-5 pl of DOTAP (Img / ml) or 3-5 pl of Lipofectamine in 1.5 ml Eppendorf tubes and incubated at room temp for 15 min. We then added an appropriate volume of Spirulina to the mixture of plasmid and DOTAP or Lipofectamine and incubated it at room temp for 10 min. The mixture was transferred to 0.2 cm cuvettes platensis and electroporated with Bio-Rad Pulser Electroporation system Gemini BV using these conditions: 200 ohms, 4kv / cm, 125pFD and 5ms.
[0303] Electroporated A. platensis was recovered from the cuvette with medium and transferred to 1.5 ml Eppendorf tubes containing 960 pl Zarrouk medium. Transformed A. platensis was then plated in 96 well plates at lOOpl / well and incubated in partial darkness in a drawer for 2-3 days. On day 3, transformed A. platensis was selected with an appropriate dose of antibiotics. We used 2.5pg / ml Spectinomycin, 6pg / ml Hygromycin B and Ipg / ml Blasticidin, depending on the selectable marker gene within the DNA construct. The selection dose was increased gradually after 20 days. A. platens is was supplemented twice a week with modified Zarrouk medium containing antibiotics and split 1 :2 two to three times. Transformed A. platensis was then moved from 96 well plates
[0304]
[0305] to successive expansion into 48 well, 24 well, and 6 well plates before transferring to 25 ml flasks in 10 ml.
[0306] EXAMPLE 7, Transformation of axenic 4. platensis without electroporation.
[0307] Axenic (UTEX 3086) was purchased from UTEX Culture Collection at the University of Texas, Austin, TX and cultured in flasks on orbital shakers at 100-150 rpm and under controlled conditions including: 75-85°F temperature, luminated with a mixture of natural and artificial light with an intensity of 213-313 lumens per square foot, with a light cycle of sunrise / sunset.
[0308] A. platensis growth was monitored by measuring optical density at 680-750 nm. Fresh medium was added when the culture density reached 1-1.2 OD. The appropriate volume of Spirulina needed for transformation was calculated using the following equation:
[0309] (40 ul X (number of transformations) X 25)
[0310] 1000 pl / ml.
[0311] The A. platensis was centrifuged at 2000xg (3000-3500 rpm on Beckman Coulter 6R centrifuge) for 45 min at 4°C. The A. platensis was then washed 3 times with 1 mM cold HEPES buffer pH 7.2-8.0 and centrifuged at 2000xg for 45 min at 4°C. The pellets were resuspended and the modified Zarrouk medium was added at a rate of 1 ml medium per planned transformation. We added 35-75pM / ml (N-acyl homoserine lactone, AHL) to the A. platensis and plate them in 96 well plates at 100 pl per well. The A. platensis was grown under controlled conditions (75-85 °F temperature, luminated with a mixture of natural and artificial lights with an intensity of (213-313 lumens per square foot) with a light cycle of sunrise / sunset) for 2-3 days and checked under the light microscopy for quorum sensing morphological changes including, irregular helical shapes, clusters of spirulina and biofilm formation. The DNA used for transformation included MEFl_30_l_V2SM_BLUE (FIG. 22 and 47) , CTXB SEKDEL (FIG. 23 and 48), CTXB_BC_SEKDEL(FIG. 24 and 49) and did not contain regions homologous to A. platensis genomic DNA and was digested with EcoRI prior to use in the transformation.
[0312] Plasmids (500 ng / transformation) w ere incubated with 3-5 pl DOTAP for 10-15 mins at room temp and diluted in Zarrouk medium before being added to Spirulina plates at 30pl / well. Transformed A. platensis was then plated in 96 well plates at lOOpl / well. On day 3, transformed A. platensis w as selected with an appropriate dose of antibiotics. We
[0313]
[0314] used 2.5pg / ml Spectinomycin, 6pg / ml Hygromycin B and Ipg / ml Blasticidin, depending on the selectable marker gene within the DNA construct. The selection dose was increased gradually after 20 days. A. platensis was supplemented twice a week with modified Zarrouk medium containing antibiotics and split 1:2 two to three times. Transformed A. platensis was then moved from 96 well plates to successive expansion into 48 well, 24 well, and 6 well plates before transferring to 25 ml flasks in 10 ml.
[0315] EXAMPLE 8, Transformation of axenic .4. platensis using N-acyl homoserine lactone.
[0316] Axenic (UTEX 3086) was purchased from UTEX Culture Collection at the University of Texas, Austin, TX and cultured in flasks on orbital shakers at 100-150 rpm and under controlled conditions including: 75-85°F temperature, luminated with a mixture of natural and artificial light with an intensity of 213-313 lumens per square foot, with a light cycle of sunrise / sunset.
[0317] A. platensis growth was monitored by measuring optical density at 680-750 nm. Fresh medium was added when the culture density reached 1-1.2 OD. The appropriate volume of Spirulina needed for transformation was calculated using the following equation:
[0318] (40 ul X (number of transformations) X 25)
[0319] 1000 pl / ml
[0320] The A. platensis was centrifuged at 2000xg (3000-3500 rpm on Beckman Coulter 6R centrifuge) for 45 min at 4°C. The A. platensis was then washed 3 times with 1 mM cold HEPES buffer pH 7.2-8.0 with centrifugation at 2000xg for 45 min at 4°C. The pellets were resuspend and modified Zarrouk medium was added at a rate of 1 ml medium per planned transformation. The 35-75 pM / ml (N-acyl homoserine lactone, AHL) was added to the A. platensis and plated in 96 well plates at 100 pl per well. We grew the A. platensis under controlled conditions (75-85 °F temperature, luminated with a mixture of natural and artificial lights with an intensity of (213-313 lumens per square foot) with a light cycle of sunrise / sunset) for 2-3 days and checked under the light microscopy for any quorum sensing morphological changes including, irregular helical shapes, clusters of spirulina and biofilm formation. The DNA used for transformation included MEF1_3O_1_V2SM_BLUE (FIG. 22 and 47) , CTXB SEKDEL (FIG. 23 and 48).
[0321]
[0322] CTXB_BC_SEKDEL(FIG. 24 and 49) and did not contain regions homologous to A. platensis genomic DNA and was digested with EcoRI prior to use in the transformation.
[0323] Plasmids (500ng / transfection) were diluted in Zarrouk medium before being added to Spirulina plates at 30 pl / well. Transformed A. platensis was then plated in 96 well plates at lOOpl / well. On day 3, transformed A. platensis was selected with an appropriate dose of antibiotics. We used 2.5pg / ml Spectinomycin, 6pg / ml Hygromycin B and Ipg / ml Blasticidin, depending on the selectable marker gene within the DNA construct. The selection dose was increased gradually after 20 days. A. platensis was supplemented twice a week with modified Zarrouk medium containing antibiotics and split 1:2 two to three times. Transformed A. platensis was then moved from 96 well plates to successive expansion into 48 well, 24 well, and 6 well plates before transferring to 25 ml flasks in 10 ml.
[0324]
[0325] REFERENCES
[0326] 1. Jester BW, Zhao El, Gewe M, Adame T, Perruzza L, Bolick DT, et al.
[0327] Development of spirulina for the manufacture and oral delivery of protein therapeutics. Nat Biotechnol. 2022;40(6):956-64. doi: 10.1038 / s41587-022-01249-7. PubMed PMID: 35314813. PMC9200632.
[0328] 2. Saveria T, Parthiban C, Seilie AM, Brady C, Martinez A, Manocha R, et al.
[0329] Needle-free, spirulina-produced plasmodium falciparum circumsporozoite vaccination provides sterile protection against pre-erythrocytic malaria in mice. NPJ Vaccines.
[0330] 2022;7(l): 113. doi: 10.1038 / s41541-022-00534-5. PubMed PMID: 36195607.
[0331] PMC9532447.
[0332] 3. Lo DD, Ling J, Eckelhoefer AH. M cell targeting by a claudin 4 targeting peptide can enhance mucosal iga responses. BMC Biotechnol. 2012;12:7. doi: 10.1186 / 1472-6750-12-7. PubMed PMID: 22413871. PMC3337280.
[0333] 4. Fathima S, Hakeem WGA, Shanmugasundaram R, Selvaraj RK. Necrotic enteritis in broiler chickens: A review on the pathogen, pathogenesis, and prevention.
[0334] Microorganisms. 2022;10(10). doi: 10.3390 / microorganismsl0101958. PubMed PMID: 36296234. PMC9610872.
[0335] 5. Ssematimba A, Malladi S, Bonney PJ, St Charles KM, Hutchinson HC, Schoenbaum M, et al. Estimating the time of highly pathogenic avian influenza virus introduction into united states poultry' flocks during the 2022 / 24 epizootic. PLoS One. 2024;19(12):e0310733. doi: 10.1371 / joumal.pone.0310733. PubMed PMID: 39671367. PMC 11642945.
[0336] 6. Namageyo-Funa A, Greene SA, Henderson E, Traore MA. Shaukat S, Bigouette JP, et al. Update on vaccine-derived poliovirus outbreaks - worldwide, January 2023-june 2024. MMWR Morb Mortal Wkly Rep. 2024;73(41):909-16. doi:
[0337] 10.15585 / mmwr.mm7341al. PubMed PMID: 39418214. PMC11486351.
[0338] 7. Lee B. Update on rotavirus vaccine underperformance in low- to middle-income countries and next-generation vaccines. HumVaccin Immunother. 2021:17(6): 1787-802. doi: 10.1080 / 21645515.2020.1844525. PubMed PMID: 33327868. PMC8115752.
[0339] 8. Guarino A, Canani RB, Russo S, Albano F, Canani MB, Ruggeri FM, et al. Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics.
[0340] 1994;93(1): 12-6. PubMed PMID: 8265305.
[0341] 9. Sarker SA, Jakel M, Sultana S, AlamNH, Bardhan PK, Chisti MJ, et al. Antirotavirus protein reduces stool output in infants with diarrhea: A randomized placebo-controlled trial. Gastroenterology. 2013;145(4):740-8.e8. doi:
[0342] 10.1053 / j.gastro.2013.06.053. PubMed PMID: 23831050.
[0343] 10. Tokuhara D, Alvarez B, Mejima M, Hiroiwa T, Takahashi Y, Kurokawa S, et al. Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection. J Clin Invest. 2013;123(9):3829-38. doi: 10.1172 / jci70266. PubMed PMID: 23925294. PMC3754275.
[0344] 11. Vega CG, Bok M, Vlasova AN, Chattha KS, Gomez-Sebastian S, Nunez C, et al. Recombinant monovalent llama-derived antibody fragments (vhh) to rotavirus vp6 protect neonatal gnotobiotic piglets against human rotavirus-induced diarrhea. PLoS Pathog.
[0345] 2013;9(5):el003334. doi: 10.1371 / joumal.ppat.1003334. PubMed PMID: 23658521.
[0346] PMC3642062.
[0347] 12. Gtinaydin G, Yu S, Graslund T. Hammarstrom L, Marcotte H. Fusion of the mouse iggl fc domain to the vhh fragment (arpl) enhances protection in a mouse model of
[0348]
[0349] rotavirus. Sci Rep. 2016;6:30171. doi: 10.1038 / srep30171. PubMed PMID: 27439689. PMC4954977.
[0350] 13. Bentes GA, Guimaraes JR, Volotao EM, Lanzarini NM, da Silva ADS, Gardinali NR, et al. Passive immunotherapy of cynomolgus monkeys with anti-rotavirus igy.
[0351] Pharmaceutics. 2024;16(9). doi: 10.3390 / pharmaceuticsl6091149. PubMed PMID:
[0352] 39339185. PMC11435195.
[0353] 14. Jenni S, Li Z, Wang Y, Bessey T, Salgado EN, Schmidt AG, et al. Rotavirus vp4 epitope of a broadly neutralizing human antibody defined by its structure bound with an attenuated-strain virion. J Virol. 2022;96(16):e0062722. doi: 10.1128 / jvi.00627-22.
[0354] PubMed PMID: 35924923. PMC9400500.
[0355] 15. Feng N, Hu L, Ding S, Sanyal M, Zhao B, Sankaran B, et al. Human vp8* mabs neutralize rotavirus selectively in human intestinal epithelial cells. J Clin Invest.
[0356] 2019;129(9):3839-51. doi: 10.1172 / jcil28382. PubMed PMID: 31403468. PMC6715378.
[0357] 16. Campbell BC. Paez-Segala MG, Looger LL, Petsko GA. Liu CF. Chemically stable fluorescent proteins for advanced microscopy. Nat Methods. 2022;19(12):1612-21. doi: 10.1038 / s41592-022-01660-7. PubMed PMID: 36344833. PMC9718679.
[0358] 17. Shaner NC, Lambert GG, Chammas A, Ni Y, Cranfill PJ, Baird MA, et al. A bright monomeric green fluorescent protein derived from branchiostoma lanceolatum. Nat Methods. 2013;10(5):407-9. doi: 10.1038 / nmeth.2413. PubMed PMID: 23524392.
[0359] PMC3811051.
[0360] 18. Ravichandran E, Al-Saleem FH, Ancharski DM, Elias MD, Singh AK, Shamim M, et al. Trivalent vaccine against botulinum toxin serotypes a, b, and e that can be administered by the mucosal route. Infect Immun. 2007;75(6):3043-54. doi:
[0361] 10.1128 / IAI.01893-06. PubMed PMID: 17371853. PMC1932861.
[0362] 19. Millar DG, Hirst TR, Snider DP. Escherichia coli heat-labile enterotoxin b subunit is a more potent mucosal adjuvant than its vlosely related homologue, the b subunit of cholera toxin. Infect Immun. 2001 ;69(5): 3476-82. doi: 10.1128 / IAI.69.5.3476-3482.2001. PubMed PMID: 11292779. PMC98315.
[0363] 20. Sanchez J, Johansson S, Lowenadler B, Svennerholm AM, Holmgren J.
[0364] Recombinant cholera toxin b subunit and gene fusion proteins for oral vaccination. Res Microbiol. 1990:141(7-8):971-9. doi: 10.1016 / 0923-2508(90)90137-f. PubMed PMID: 2101488.
[0365] 21. Suzuki H, Kondoh M, Kakutani H, Yamane S, Uchida H, Hamakubo T, et al. The application of an alanine-substituted mutant of the c-terminal fragment of Clostridium perfringens enterotoxin as a mucosal vaccine in mice. Biomaterials. 2012:33(1 ):317-24. doi: 10.1016 / j. biomaterials.2011.09.048. PubMed PMID: 21983135.
[0366] 22. Kawata Y, Yano S, Kojima H, Toyomizu M. Transformation of spirulina platensis strain cl (arthrospira sp. Pcc9438) with tn5 transposase-transposon DNA-cation liposome complex. Mar Biotechnol (NY). 2004;6(4):355-63. doi: 10.I007 / S10I26-003-0037-1. PubMed PMID: 15136915.
[0367] 23. Nguyen DH, You SH. Vo AN, Ngo HT, Van Nguyen K. Duong MT, et al.
[0368] Optimized doxycycline-inducible gene expression system for genetic programming of tumor-targeting bacteria. Mol Imaging Biol. 2022;24(l):82-92. doi: 10.1007 / sl 1307-021-01624-x. PubMed PMID: 34403085. PMC8760206.
[0369] 24. Farruggio AP. Bhakta MS, Calos MP. Use of the dice (dual integrase cassette exchange) system. Methods Mol Biol. 2017;1642:69-85. doi: 10.1007 / 978-1-4939-7169-5 5. PubMed PMID: 28815494.
[0370] 25. Liu Z, Chen O, Wall JBJ, Zheng M, Zhou Y, Wang L, et al. Systematic comparison of 2a peptides for cloning multi-genes in a polycistronic vector. Sci Rep.
[0371]
[0372] 2017;7(l):2193. doi: 10.1038 / s41598-017-02460-2. PubMed PMID: 28526819.
[0373] PMC5438344.
[0374] 1. Fox H, Knowlson S, Minor PD, Macadam AJ. Genetically Thermo-Stabilised, Immunogenic Poliovirus Empty Capsids: a Strategy for Non-replicating Vaccines. PLoS Pathog. 2017;13(l):el006117. Epub 20170119. doi: 10.1371 / joumal.ppat.l006117.
[0375] PubMed PMID: 28103317: PubMed Central PMCID: PMCPMC5245777.
[0376] 2. Sherry L, Bahar MW, Porta C, Fox H, Grehan K, Nasta V, et al. Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines. Nat Commun. 2025;16(l):831. Epub 20250118. doi: 10.1038 / s41467-025-56118-z. PubMed PMID: 39827284; PubMed Central PMCID: PMCPMC11742952.
[0377] 3. Sherry L, Swanson JJ, Grehan K, Xu H, Uchida M, Jones IM, et al. Protease-Independent Production of Poliovirus Virus-like Particles in Pichia pastoris: Implications for Efficient Vaccine Development and Insights into Capsid Assembly. Microbiol Spectr.
[0378] 2023;ll(l):e0430022. Epub 20221212. doi: 10.1128 / spectrum.04300-22. PubMed PMID: 36507670; PubMed Central PMCID: PMCPMC9927490.
[0379] 4. Gotzke H, Kilisch M, Martinez-Carranza M, Sograte-Idrissi S, Rajavel A, Schlichthaerle T, et al. The ALFA-tag is a highly versatile tool for nanobody -based bioscience applications. Nat Commun. 2019;10(l):4403. Epub 20190927. doi:
[0380] 10.1038 / s41467-019-12301-7. PubMed PMID: 31562305; PubMed Central PMCID:
[0381] PMCPMC6764986.
[0382] 5. Cela I, Dufrusine B, Rossi C, Luini A, De Laurenzi V, Federici L, et al. KDEL Receptors: Pathophysiological Functions, Therapeutic Options, and Biotechnological Opportunities. Biomedicines. 2022;10(6). Epub 20220525. doi:
[0383] 10.3390 / biomedicinesl0061234. PubMed PMID: 35740256; PubMed Central PMCID: PMCPMC9220330.
[0384] Each patent, patent application, and publication, including websites cited throughout specification are incorporated herein by reference. Similarly, the SEQ ID NOs which are referenced herein and which appear in the appended Sequence Listing are incorporated by reference. While the invention has been described with reference to particular embodiments, it will be appreciated that modifications can be made without departing from the spirit of the invention. Such modifications are intended to fall within the scope of the appended claims.
Claims
CLAIMS:
1. A recombinant spirulina comprising an expression cassete, the expression cassete comprising a nucleic acid comprising an exogenous promoter sequence operably linked to a sequence encoding a polypeptide.
2. A recombinant spirulina of claim 1 in which the expression cassete was incorporated into the genome using processes independent of homologous recombination.
3. The recombinant spirulina of claim 1, wherein the expression cassete does not contain an endogenous spirulina gene and / or wherein the homologous domains within the expression cassete have not undergone homologous recombination during their incorporation into the spirulina genome.
4. The recombinant spirulina of claim 1, wherein the expression cassete contains one or more recognition sequences capable of mediating site-specific recombination.
5. The recombinant spirulina of claim 1, wherein the exogenous promoter sequence is a high efficiency heterologous promoter sequence, optionally wherein the heterologous promoter sequence comprises a J23119 promoter sequence.
6. A recombinant spirulina of claim 1 in which the polypeptide is capable of inducing a mucosal immune response.
7. The recombinant spirulina of claim 1, wherein the expression cassete encodes a polypeptide sequence of interest8. The recombinant spirulina of claim 7, wherein the polypeptide sequence of interest provides resistance to the toxic effects of blasticidin.
9. The recombinant spirulina of claim 7, wherein the polypeptide sequence of interest provides resistance to the toxic effects of hygromycin.
10. The recombinant spirulina of claim 7, wherein the polypeptide sequence of interest is an antibody or a vaccine (e.g. rotavirus or poliovirus)11. The recombinant spirulina of claim 7, in which the polypeptide is a Clostridium toxin or a fusion protein comprising a Clostridium toxin.
12. The recombinant spirulina of claim 11, in which the clostridial toxin is derived from C. botulinum, C. perfringens, or C. difficile.
13. The recombinant spirulina of claim 11, in which the clostridial toxin is fused to the NetB toxin, influenza hemagglutinin (HA), or a fragment thereof.
14. The recombinant spirulina of claim 7, in which the polypeptide is a cholera toxin or a fusion protein comprising a cholera toxin.
15. The recombinant spirulina of claim 14, in which the cholera toxin is the cholera toxin B subunit.
16. The recombinant spirulina of claim 14, in which the cholera toxin is the cholera toxin B subunit fused to a poliovirus antigen (BC loop polypeptide).
17. The recombinant spirulina of claim 14, in which the cholera toxin is the cholera toxin B subunit expressed with a c-terminal KDEL endoplasmic reticulum retention sequence comprising the amino acids Lys-Asp-Glu-Leu.
18. The recombinant spirulina of claim 7, in which the polypeptide is an E. coli heat labile enterotoxin.
19. The recombinant spirulina of claim 18. in which the E. coli heat labile enterotoxin is the enterotoxin B subunit.
20. The recombinant spirulina of claim 18, in which the E. coli heat labile enterotoxin is the double mutant heat-labile enterotoxin B, specifically LT(R192G / L211 A) .
21. A method of generating the strain of spirulina of any one of claims 1 to 20 comprising contacting a native spirulina with the expression cassette.
22. The method of claim 21, wherein the native spirulina is in an axenic population.
23. The method of claim 21 or 22, further comprising treating with AHL (or other quorum sensing molecule).
24. The method of any one of claims 21-23, wherein the expression cassette comprises an antibiotic resistance gene, further comprising contacting the spirulina with the antibiotic (Blasticidin, Hygromycin B).
25. The method of one of claims 21-24, further comprising performing electroporationor contacting the spirulina and / or expression cassette with cationic lipids that promote transformation of the spirulina.
26. A method of generating a recombinant spirulina having a genome comprising an expression cassette, the method comprising:a) contacting spirulina with a donor nucleic acid comprising a DNA sequence flanked by recombinase recognition sites,b) contacting spirulina with nucleic acids encoding one or more recombinases, thereby effecting a swap of ectopic DNA sequences within the genome with donor DNA sequences.
27. The recombinant spirulina or method of any one of claims 1 to 26. wherein the expression cassette has attP sites.
28. The recombinant spirulina or method of claim 27, wherein the attP sites are specific for the transposases BxBl and PhiC21.
29. The method of any one of claims 21-28, further comprising co-transfection with plasmids expressing transposases.
30. A method of mucosal administration of a protein of interest, the method comprising administering a recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding the protein of interest.
31. A method of mucosal vaccination of a subject with a protein of interest, the method comprising administering a recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding the protein of interest.
32. A method of mucosal vaccination of a subject with a protein of interest, in which the protein is capable of specific interaction with mucosal microfold cells, the method comprising administering a recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding the protein of interest, thereby inducing a mucosal specific (IgA) immune response.
33. The method of any one of claims 30-32 wherein the protein of interest comprises a Clostridium toxin or a fusion protein comprising a Clostridium toxin.
34. The recombinant spirulina or method of any one of claims 1 to 33 wherein the expression cassette lacks homology or lacks flanking sequences with homology to spirulina genome.
35. The recombinant spirulina or method of any one of claims 1 to 34 wherein the expression cassette does not contain an endogenous spirulina gene or a sequence sharing greater than 95% identity with a spirulina gene.
36. The recombinant spirulina or method of any one of claims 1 to 35 wherein the recombinant spirulina has a full-complement of genes expressed by a parental strain and / or the expression cassette does not disrupt expression of an endogenous spirulina gene locus.
37. A recombinant spirulina produced according to the method of any one of claims 21 to 29.
38. A method of inducing a mucosal immune response in a subject, the method comprising administering the recombinant spirulina of any one of claims 1 to 37 to the subject, optionally wherein the administration is via an oral route.
39. A recombinant spirulina comprising an expression cassette, the expression cassette comprising a nucleic acid comprising an exogenous promoter operably linked to a sequence encoding a cholera toxin or a fusion protein comprising a cholera toxin.
40. A recombinant spirulina comprising an expression cassette, said expression cassette comprising a nucleic acid comprising an exogenous promoter and a sequence encoding a heat-labile toxin or a fusion protein comprising a heat-labile toxin.
41. The recombinant spirulina of claim 39 or 40, wherein the fusion protein comprises a poliovirus vpl or fragment thereof.
